Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has shared an announcement.
Lumos reported strong momentum in the first half of FY26, underpinned by a six-year exclusive U.S. distribution agreement worth up to US$317 million for FebriDx with PHASE Scientific and the completion and submission of its CLIA waiver clinical study to the FDA. The company also commenced a BARDA-funded paediatric CLIA-waived study, secured 100% Medicare reimbursement coverage across all seven U.S. MAC jurisdictions, and strengthened its cash position with US$2.75 million in non-dilutive grants and a A$5 million loan facility, supporting operations until the anticipated CLIA waiver decision by the end of Q1 2026.
Operationally, Lumos saw FebriDx revenue rise by US$1.4 million over the prior corresponding period and achieved positive operating cash flow of US$0.8 million, reflecting a US$7.1 million improvement. These milestones collectively improve the company’s commercial readiness for broad U.S. rollout of FebriDx, enhance its reimbursement footing, and de-risk its near-term funding needs, positioning it more competitively in the point-of-care diagnostics market ahead of the key FDA CLIA waiver outcome.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.29 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd., based in Melbourne and listed on the ASX, develops rapid point-of-care diagnostic technologies. Its flagship product FebriDx is designed to differentiate bacterial from viral infections, with a key strategic focus on expanding access in the U.S. market through regulatory approvals, reimbursement coverage, and distribution partnerships.
Average Trading Volume: 3,965,884
Technical Sentiment Signal: Buy
Current Market Cap: A$202.3M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.